Systemic lupus Erythematosus and IgA multiple myeloma: A rare association?

Medical Oncology

Volumn 24, Issue 4, 2007, Pages 445-448

  Bila, J ^a   Suvajdzic, N ^a   Elezovic, I ^a   Colovic, M ^a   Boskovic, D ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Multiple myeloma; Systemic lupus Erythematosus

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CHLOROQUINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; MELPHALAN; METHYLPREDNISOLONE; STEROID; THALIDOMIDE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTEBRA FRACTURE;

FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULIN A; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINS;

EID: 36249018931     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0047-3     Document Type: Article

References (38)

1. Pettersson T, Pukkala E, Teppo L, Friman C. Increase risk of cancer in patients with systemic lupus Erythematosus. Ann Rheum Dis 1992;51(4):437-9.
2. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus Erythematosus. Arthritis Rheum 1996;39(6):1050-4.
3. Mellemkjaer L, et al. Non-Hodgkin's lymphomas and other cancers among a cohort of patients with systemic lupus Erythematosus. Arthritis Rheum 1997;40(4):761-8.
4. Vineis P, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000;54(6):431-6.
5. Cibere J, Sibley J, Haga M. Systemic lupus Erythematosus and the risk of malignancy. Lupus 2001;10(6):394-400.
6. Xu Y, Wiernik PH. Systemic lupus Erythematosus and B-cell hematologic neoplasm. Lupus 2001;10(12):841-50.
7. Afeltra A, et al. Systemic lupus Erythematosus and multiple myeloma: a rare association. Semin Arthritis Rheum 1997;26(6):845-9.
8. Jordan E, Burnstein SL, Calabro JJ, Henderson ES. Multiple myeloma complicating the course of seronegative systemic lupus Erythematosus. Arthritis Rheum 1978;21(2):260-5.
9. Pehamberger M, Diem E, Konrad K. Systemic lupus Erythematosus with multiple myeloma. Acta Derm Venereol 1978;58(6):527-30.
10. Solary E, et al. Systemic lupus Erythematosus occurring in a patient with multiple myeloma. Arthrtis Rheum 1986;29(7):933-4.
11. Isobe T, Osserman EF. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci 1971;190:507-18.
12. Butler RC, Thomas SM, Thomson JM, Keat ACS. Anaplastic myeloma in systemic lupus Erythematosus. Ann Rheum Dis 1984;43:653-5.
13. Sendagorta E, Matarredona J, Brieva JA, Rodriguez ML, Ledo A. Systemic lupus Erythematosus in association with smoldering multiple myeloma. J Am Acad Dermatol 1987;16(1 pt 1):135-6.
14. Vaiopoulos G, Konstatopoulos K, Mantzourani M, Kaklamanis P. Multiple myeloma associated with systemic lupus Erythematosus. Leuk Lymphoma 2003;44(5):893-4.
15. Urbanska-Rys H, et al. Multiple myeloma in a patient with systemic lupus Erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma. Leuk Lymphoma 2004;45(9):1913-8.
16. Menon S, Snaith J, Isenberg DA. The association of malignancy with SLE.: an analysis of 150 patients under long term review. Lupus 1993;2(3):177-81.
17. Munzert G, Frickhofen N, Bauditz J, Schreiber S, Herrmann F. Concomitant manifestations of systemic lupus Erythematosus and low-grade non-Hodgkin's lymphoma. Leukemia 1997;11(8):1324-8.
18. Ramsey-Goldman R, Clarke A. Double trouble: are lupus and malignancy associated? Lupus 2001;10(6):388-91.
19. Valeriano J. Malignancy and rheumatic disease. Cancer Control 1997;4(3):236-44.
20. Agudelo CA, Schumacher HR, Glick JH, Molina J. Non-Hodgkin's lymphoma in systemic lupus Erythematosus: report of 4 cases with ultrastructural studies in 2. J Rheumatol 1981;8(1):69-78.
21. Green JA, Dawson AA, Walker W. Systemic lupus Erythematosus and lymphoma. Lancet 1978;2(8093):753-6.
22. Yoinou P, Le Corre R, Dueymes M. Autoimmune diseases and monoclonal gammopathies. Clin Exp Rheumatol 1996;14 Suppl 14:55-8.
23. Rubin L, Urowitz MB, Pruzanski W. Systemic lupus Erythematosus with paraproteinemia. Arthritis Rheum 1984;27(6):638-44.
24. Kelly C, Baird G, Foster H, Hosker H, Griffiths I. Prognostic significance of paraproteinemia in rheumatoid arthritis. Ann Rheum Dis 1991;50(5):290-4.
25. Schafer AI, Miller JB. Association of IgA multiple myeloma with pre-existing disease. Br J Haematol 1979;41(1):19-24.
26. Facon T, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97(6):1566-71.
27. Fonseca R, Oken MM, Greipp RP. Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001;98(4):1271-2.
28. Avet-Loiseau H, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58(24):5640-5.
29. Chang H, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125(1):64-8.
30. Jaksic W, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J C Oncol 2005;23(28):7069-73.
31. Chesi M, et al. Frequent translocation t(4;14)(p16.3;q.32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genetics 1997;16(3):260-4.
32. Richelda R, et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves fibroblast growth receptor 3 gene. Blood 1997;90(10):4062-70.
33. Chesi M, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729-36.
34. Remmers EF, Sano H, Wider RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991;21(3):191-9.
35. Boumpas DT, Eleftheriades EG, Barez S, Tsokos GC. Oncogene expression and regulation in normal lymphocytes from patients with autoimmune disorders. Anticancer Res 1988;8(5A):977-84.
36. Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 2002;100(10):3819-21.
37. Brown RD, Pope B, Luo XF, Gibson J, Joshua D. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymphoma 1994;16(1-2):147-56.
38. Standal T, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100(8):3002-7.